Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Haller, PM; Gremmel, T; Auer, J; Binder, RK; Delle-Karth, G; Frick, M; Gwechenberger, M; Hoppe, UC; Purerfellner, H; Siostrzonek, P; Zweiker, R; Scherr, D; Martinek, M; Neunteufl, T; Berger, R; Alber, H; Stuhlinger, M; Frank, H; Lechleitner, P; Lang, IM; Niessner, A; Huber, K.
Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention: Austrian Expert Recommendations
J KARDIOL. 2018; 25(7-8): 194-201.
Web of Science


Co-Autor*innen der Med Uni Graz
Scherr Daniel
Zweiker Robert

Patients with atrial fibrillation who undergo percutaneous coronary intervention and placement of a stent for coronary artery disease are in need for anti-platelet therapy in addition to oral anticoagulation. Due to the high bleeding risk under the combination of these therapies efforts have been made to reduce the intensity of therapy in these patients. The dual antithrombotic therapy (DAT) consisting of an oral anticoagulant and a P2Y12 inhibitor represents one alternative to the commonly used triple antithrombotic therapy (TAT), which requires the intake of a vitamin K-antagonist (VKA) or a non-vitamin-K-anatgonist oral anticoagulant (NOAC), a P2Y12 inhibitor and acetylsalicylic acid. Recently, three large studies have been published showing superiority of DAT over TAT with respect to the occurence of bleeding complications. At the same time, the risk of ischemic events, like myocardial infarction and stent thrombosis, seems to be comparable. This review summarizes the available evidence and aims at providing recommendations for daily clinical practice in addition to the current guidelines published by the European Society of Cardiology.

Find related publications in this database (Keywords)
atrial fibrillation
coronary heart disease
dual antithrombotic therapy
oral anticoagulation
© Med Uni Graz Impressum